The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as a first-line treatment for adults with extensive-stage, small-cell lung cancer (ES-SCLC) in combination with chemotherapy.

The approval is for use along with etoposide plus either carboplatin or cisplatin. It was based on results of a phase 3 clinical trial, in which Imfinzi with chemotherapy improved overall survival for ES-SCLC patients.

Imfinzi is also approved in the U.S., Japan and several other countries for the same indication.